No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ZVRA Zevra Therapeutics
- 4.450
- -0.100-2.20%
Close Jun 18 16:00 ET
186.25MMarket Cap-3371P/E (TTM)
4.630High4.450Low236.85KVolume4.570Open4.550Pre Close1.07MTurnover0.66%Turnover RatioLossP/E (Static)41.85MShares7.28052wk High3.82P/B160.64MFloat Cap3.89052wk Low--Dividend TTM36.10MShs Float418.400Historical High--Div YieldTTM3.96%Amplitude2.560Historical Low4.497Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Breakeven On The Horizon For Zevra Therapeutics, Inc. (NASDAQ:ZVRA)
Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA (Sodium Phenylbutyrate), a Treatment for Certain Urea Cycle Disorders
Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA (Sodium Phenylbutyrate), a Treatment for Certain Urea Cycle Disorders
Roth MKM Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $19
Roth MKM analyst Jonathan Aschoff maintains $Zevra Therapeutics(ZVRA.US)$ with a buy rating, and maintains the target price at $19.According to TipRanks data, the analyst has a success rate of 28.9% a
Express News | Zevra Therapeutics Inc Files for Mixed Shelf Offering of up to $350 Mln- SEC Filing
Express News | Zevra Therapeutics Announces Phase 2 Trial Results For KP1077 In Idiopathic Hypersomnia Presented At SLEEP 2024
Express News | Zevra Therapeutics Inc - Kp1077 Was Well Tolerated
Comments
$Zevra Therapeutics(ZVRA.US$
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting
Zevra Therapeutics announced positive final results from its Phase 2 clinical trial of KP1077 for idiopathic hypersomnia (IH) at SLEEP 2024. KP1077 showed significant improvements in daytime sleepiness, sleep inertia, and brain fog with good tolerance across various doses. The European Commission granted Orphan Drug De...
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting
Zevra Therapeutics announced positive final results from its Phase 2 clinical trial of KP1077 for idiopathic hypersomnia (IH) at SLEEP 2024. KP1077 showed significant improvements in daytime sleepiness, sleep inertia, and brain fog with good tolerance across various doses. The European Commission granted Orphan Drug De...
$Zevra Therapeutics(ZVRA.US$ Reuters· 5 mins ago
Zevra Therapeutics Inc - Reported Positive Topline Results From Kp1077 Phase 2 Trial in Idiopathic Hypersomnia
Zevra Therapeutics Inc - Reported Positive Topline Results From Kp1077 Phase 2 Trial in Idiopathic Hypersomnia
$Zevra Therapeutics(ZVRA.US$ Zevra Therapeutics Metabolic Disorder Treatment Shows 'Meaningful Slowing of Disease Progression'
MT Newswires· 1 min ago
MT Newswires· 1 min ago
2
$Zevra Therapeutics(ZVRA.US$
NEWS
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
New long-term real-world data from Zevra's Expanded Access Program for Arimoclomol in treating Niemann-Pick Disease Type C was highlighted at the SIMD 45th Annual Meeting.
The data showed a consistent safety profile and a clinically meaningful slowing of disease progression in adults with NPC.
...
NEWS
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
New long-term real-world data from Zevra's Expanded Access Program for Arimoclomol in treating Niemann-Pick Disease Type C was highlighted at the SIMD 45th Annual Meeting.
The data showed a consistent safety profile and a clinically meaningful slowing of disease progression in adults with NPC.
...
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg